statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dr Reddy’s reported better-than-expected net profit of Rs 1,307 crore for the March quarter, up 36 percent from the year-ago period

Dr Reddy’s to launch over 20 products in US in FY25

While Revlimid push helped Dr Reddy's report healthy Q4 earnings, a lack of strong US launch pipeline, high R&amp;D costs and weakness in base business are expected to put near-term pressure on the drugmaker.

Dr Reddy's healthy Q4 results fail to impress brokerages amid lack of growth triggers

Agarwal will also cease to be a member of the Management Council and Senior Management Personnel of the company and will continue to be available with till August 31, 2024.

Dr Reddy's Labs CFO Parag Agarwal to retire on July 31, MV Narasimham elevated

Dr Reddy's Q4 earnings: Revenue rose 12 percent from a year earlier to Rs 7,083 crore

Dr Reddy's Q4 results: Net profit up 36% to Rs 1,307 crore, Rs 40/share dividend declared

The volatility index (VIX) bouncing back suggests challenges ahead, while on the downside, a breach below 22,300 could lead to a slide towards 22,100–22,000 on the Nifty.

Three stocks that can deliver up to 10% in the short term; watch out for the rising VIX

The Head of Institutional Equities at HDFC Securities expects consumption demand to witness a slight pickup in FY25 and suggests adding exposure to the FMCG sector on a selective basis.

Daily Voice | These 4 pharma stocks to benefit from change in 2 trends: HDFC Securities' Unmesh Sharma

State Bank of India was the second largest gainer in the Nifty 50 on Thursday and ended at new closing high. The stock has formed a Bullish Marubozu kind of candlestick pattern on the daily charts, with robust volumes.

Trade Spotlight | Your blueprint for State Bank of India, Firstsource Solutions, Dr Reddy's Labs counters today

Dr. Reddy’s Laboratories Share Price | Nerivio is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe.

Dr Reddy’s dips despite launching migraine management device in Europe

After its launch in the European market, Nerivio will be introduced in South Africa later in April, followed by Spain and the UK

Dr Reddy's launches drug-free migraine management device in Germany

After witnessing consistent double-digit growth in branded formulations business in recent years, growth in the domestic formulation segment has moderated to high single digits

Steady US sales to bring a healthy quarter for pharma sector

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Watchers	384
52-Wk Low	4,384.05
52-Wk High	6,600.00

Volume	988,140.00
52-Wk High	6,600.00
52-Wk Low	4,384.05

DRREDDY.NSE Dr. Reddy`s Laboratories Ltd.

About

Feed

News

Sentiment

Fundamentals